In this episode of MedInsights Unleashed, Dr. Ari Rosenberg, MD, Assistant Professor of Medicine at the University of Chicago Medical Center, returns to discuss a rapidly changing era in head and neck cancer. He examines the practice-changing KEYNOTE-689 data establishing a role for perioperative immunotherapy in selected surgically treated patients, while explaining the important differences between HPV-associated and HPV-unrelated disease.

Ari also explores emerging approaches to treatment de-escalation in HPV-positive disease, the growing potential of ctDNA and minimal residual disease to identify recurrence risk, and promising therapies for recurrent and metastatic disease, including bispecific antibodies, antibody-drug conjugates and new combinations. His message is one of genuine progress, but also the continued need for clinical trials, collaboration and better outcomes for patients.